Quibron-T
$ 43,00 – $ 492,00Price range: $ 43,00 through $ 492,00
Ranitidine
$ 45,00 – $ 136,00Price range: $ 45,00 through $ 136,00
Ranexa
$ 49,00 – $ 310,00Price range: $ 49,00 through $ 310,00
Ranexa is a specialized cardiovascular medication containing the active ingredient ranolazine. It is primarily indicated for the chronic treatment of stable angina pectoris in adult patients. This medication works by optimizing cardiac metabolism to help the heart function more efficiently during physical activity. Regular use can lead to a significant reduction in the frequency of chest pain episodes and improved exercise tolerance. Ranexa provides a reliable solution for managing the persistent symptoms associated with coronary artery disease.
Active substance: Ranolazine
SKU:
Ranexa
Categories: Blood Pressure, Heart Disease
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Ranexa – Information for Patients and Caregivers
Ranexa belongs to a class of cardiovascular medications known as antianginal agents that work via metabolic and ion channel modulation rather than primary hemodynamic alterations. It is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic angina.
Unlike traditional antianginal therapies such as beta-blockers or nitrates, Ranexa reduces ischemic symptoms without causing clinically significant reductions in resting heart rate or blood pressure. It may be prescribed alone or in combination with other cardiovascular therapies under appropriate clinical supervision.
| Parameter | Detail |
|---|---|
| Drug name | Ranexa |
| Active ingredient (INN) | Ranolazine |
| Therapeutic class | Antianginal agent |
| Dosage form | Extended-release oral tablets (500 mg, 1000 mg) |
| Route of administration | Oral |
| Prescription status | Prescription (Rx only) |
| Primary purpose | Treatment of chronic angina pectoris |
What it’s used for
Ranexa is indicated for the symptomatic treatment of chronic angina pectoris in adult patients. Chronic angina is a cardiovascular condition characterized by recurrent chest discomfort or pain occurring when the heart muscle does not receive adequate oxygen-rich blood flow during physical exertion or emotional stress. Ranexa is intended for long-term maintenance management to decrease the frequency of anginal attacks and increase exercise capacity in affected individuals.
It is important to emphasize that Ranexa is not indicated for the immediate relief of acute anginal episodes. Acute angina attacks require fast-acting short-acting sublingual nitrates. Ranexa can be prescribed as monotherapy or added to existing anginal treatment regimens involving beta-blockers, calcium channel blockers, nitrates, antiplatelet therapies, lipid-lowering agents, or blood pressure medications under medical supervision.
How the drug works
The precise therapeutic mechanism of Ranexa (ranolazine) is not completely elucidated, but its cardiac effects are distinct from conventional antianginal drugs. Ranolazine selectively inhibits the late inward sodium current ($I_{Na}$) in myocardial cells during cardiac action potentials. Under ischemic conditions, cellular hypoxia causes an abnormal increase in late sodium influx, leading to intracellular sodium overload.
This elevated intracellular sodium level subsequently disrupts the sodium-calcium exchanger, causing intracellular calcium overload within the myocardium. By suppressing the late sodium current, Ranexa attenuates intracellular calcium accumulation, thereby reducing myocardial mechanical tension and improving microvascular diastolic relaxation. Notably, this therapeutic action occurs without producing significant decreases in heart rate or systemic vascular resistance.
Dosing schedule
Ranexa is formulated as extended-release tablets intended for oral administration. The typical starting dosage prescribed for adult patients is 500 mg administered orally twice daily. Based on clinical response, symptoms, and individual patient tolerability, the treating healthcare provider may titrate the dosage up to a maximum recommended limit of 1000 mg twice daily.
Tablets must be swallowed whole with fluid and must never be crushed, chewed, broken, or dissolved, as altering the extended-release matrix can cause rapid drug release and potential systemic toxicity. Ranexa may be taken with or without meals. If a patient experiences specific adverse effects such as severe dizziness or nausea, the dosage may require downward adjustment or discontinuation under medical guidance.
How it’s absorbed and eliminated
Following oral administration of Ranexa extended-release tablets, ranolazine is absorbed across the gastrointestinal tract, with peak plasma concentrations ($C_{max}$) achieved between 2 and 5 hours post-dose. The absolute bioavailability of ranolazine ranges between 35% and 55% due to presystemic first-pass metabolism. Steady-state plasma concentrations are generally attained within 3 days of twice-daily dosing.
Ranolazine is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4, with minor metabolic contributions from CYP2D6. The drug is also a substrate and moderate inhibitor of P-glycoprotein (P-gp). Less than 5% of the parent compound is excreted unchanged in urine and feces. The terminal elimination half-life of ranolazine is approximately 7 hours.
What not to combine
Ranexa has significant potential for pharmacokinetic drug-drug interactions due to its reliance on hepatic CYP3A enzymes and P-glycoprotein transporters. Co-administration of Ranexa with strong CYP3A inhibitors–including ketoconazole, itraconazole, clarithromycin, and ritonavir–is strictly contraindicated because these agents significantly elevate ranolazine plasma concentrations and increase the risk of serious side effects.
Similarly, strong CYP3A inducers such as rifampin, carbamazepine, phenobarbital, and St. John’s wort substantially lower plasma concentrations of ranolazine, compromising its therapeutic efficacy. Moderate CYP3A inhibitors (such as diltiazem, verapamil, and erythromycin) require limiting the maximum dose of Ranexa to 500 mg twice daily. Additionally, caution is warranted when co-administering Ranexa with drugs that prolong the QTc interval or substrates of CYP2D6 and P-gp, such as digoxin and simvastatin.
Adverse reactions
Clinical trials and post-marketing surveillance indicate that Ranexa is generally tolerated, though adverse effects can occur. The most commonly reported side effects include dizziness, headache, constipation, and nausea. Patients may also experience asthenia, palpitations, or peripheral edema during the course of therapy.
A critical safety consideration with Ranexa is its dose-dependent effect on the cardiac conduction system, specifically QTc interval prolongation. Prolongation of the QTc interval can increase the risk of ventricular arrhythmias, including Torsades de Pointes. Other less common adverse events include acute renal failure reported in patients with pre-existing severe renal impairment, syncope, tinnitus, and hypersensitivity reactions such as skin rash or urticaria.
Before you take it
Before initiating treatment with Ranexa, healthcare providers must conduct a comprehensive evaluation of the patient’s medical history. Ranexa is contraindicated in patients with hepatic cirrhosis or severe hepatic impairment, as impaired liver function leads to markedly increased drug exposure. It is also contraindicated in patients currently receiving strong CYP3A inhibitors or inducers.
Caution is necessary when prescribing Ranexa to patients with pre-existing QTc prolongation, a family history of congenital long QT syndrome, or those taking other QTc-prolonging drugs. Baseline and periodic electrocardiogram (ECG) assessments may be recommended. Patients with moderate-to-severe renal impairment require close monitoring of renal function, as ranolazine clearance is reduced and serum creatinine levels may rise during treatment.
What to avoid while taking it
Patients taking Ranexa should avoid consuming grapefruit and grapefruit juice. Grapefruit products inhibit the CYP3A enzyme system in the intestinal wall, which can significantly increase blood levels of ranolazine and elevate the risk of adverse reactions, particularly QTc prolongation and severe dizziness.
Alcohol consumption should be discussed with a treating physician prior to starting treatment. While direct pharmacokinetic interactions between alcohol and Ranexa are limited, alcohol consumption can cause hypotension or dizziness, potentially compounding central nervous system side effects such as lightheadedness and unsteadiness.
If you skip a dose
If a patient misses a scheduled dose of Ranexa, they should skip the missed tablet entirely and take the next dose at the regular scheduled time. Patients should never double the dose or take extra tablets to make up for a missed dose, as doubling doses increases the risk of excessive drug accumulation and potential cardiac electrical alterations.
Maintaining a consistent twice-daily dosing schedule helps ensure stable therapeutic drug concentrations in the bloodstream. If multiple doses are missed consecutively, the patient should contact their prescribing healthcare provider or pharmacist for guidance on resuming therapy safely.
Special populations
The safety and efficacy of Ranexa in pediatric patients under 18 years of age have not been established; therefore, use in children is not recommended. In elderly patients (65 years of age and older), clinical studies have demonstrated similar safety and efficacy profiles compared to younger adults, though age-related declines in renal or hepatic function warrant careful monitoring and potential dose adjustment.
Regarding pregnancy, data on the use of Ranexa in pregnant women are limited. Animal reproduction studies have not demonstrated direct fetal toxicity, but Ranexa should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether ranolazine is excreted in human milk; caution should be exercised when administering Ranexa to a nursing mother, weighing nursing benefits against clinical need.
Storage and expiration
Ranexa extended-release tablets should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) according to U.S. Pharmacopeia guidelines. Keep the medication in its original container, tightly closed, and protected from excessive moisture and light.
Keep Ranexa out of the reach and sight of children and pets. Do not use tablets past the expiration date printed on the bottle or packaging. Unused or expired medication should be disposed of properly through local pharmacy take-back programs or in accordance with federal and state waste disposal guidelines, avoiding flushing down toilets unless explicitly instructed.
Common questions
Can Ranexa be used to stop an acute angina attack?
No. Ranexa is designed for long-term management to prevent and reduce the frequency of chronic angina attacks. It does not work rapidly enough to relieve an acute onset of chest pain. Patients should always keep fast-acting sublingual nitroglycerin or an immediate-release short-acting nitrate as directed by their physician for acute episodes.
Does Ranexa lower blood pressure or heart rate like other heart medications?
Ranexa does not significantly lower resting heart rate or blood pressure compared to traditional antianginal drugs such as beta-blockers or calcium channel blockers. Its primary mechanism involves blocking late sodium channels in cardiac cells to reduce intracellular calcium buildup during ischemia.
What should I do if I experience dizziness while taking Ranexa?
Dizziness is one of the most common side effects associated with Ranexa. If you feel dizzy or lightheaded, sit or lie down immediately to prevent falls. Contact your prescribing physician, as persistent or severe dizziness may indicate a need to adjust your dose or re-evaluate concurrent medications.
Why can’t I crush or split Ranexa tablets?
Ranexa is formulated in a specialized extended-release matrix that gradually releases the active drug over time. Crushing, chewing, or breaking the tablet destroys this controlled release mechanism, causing the entire dose to be released into your bloodstream all at once, which can lead to dangerously high blood levels and adverse toxicity.
Is it safe to take Ranexa alongside other heart medications?
Ranexa is frequently prescribed in combination with standard antianginal and cardiovascular treatments, including nitrates, beta-blockers, ACE inhibitors, and lipid-lowering therapies. However, certain medications–especially moderate-to-strong CYP3A inhibitors or drugs that prolong the QT interval–can interact dangerously with Ranexa. Always provide your complete medication list to your prescribing physician and pharmacist before starting Ranexa.
In accordance with FDA requirements.
The information presented here is not a substitute for professional medical advice.
Additional information
| Dosage |
500mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills ,120 pills ,180 pills ,270 pills ,360 pills |
| Ενεργός Ουσία |
Related products
Adalat
$ 41,00 – $ 267,00Price range: $ 41,00 through $ 267,00
Active substance: Nifedipine
More Details
This product has multiple variants. The options may be chosen on the product page
Altace
$ 40,00 – $ 322,00Price range: $ 40,00 through $ 322,00
Active substance: Ramipril
More Details
This product has multiple variants. The options may be chosen on the product page
Arjuna
$ 63,00 – $ 72,00Price range: $ 63,00 through $ 72,00
Active substance: Arjuna (Terminalia arjuna) bark extract
More Details
This product has multiple variants. The options may be chosen on the product page
Assurans
$ 50,00 – $ 70,00Price range: $ 50,00 through $ 70,00
Active substance: Sildenafil Citrate
More Details
This product has multiple variants. The options may be chosen on the product page
Capoten
$ 42,00 – $ 323,00Price range: $ 42,00 through $ 323,00
Active substance: Captopril
More Details
This product has multiple variants. The options may be chosen on the product page
Digoxin
$ 48,00 – $ 152,00Price range: $ 48,00 through $ 152,00
Active substance: digoxin
More Details
This product has multiple variants. The options may be chosen on the product page
Doxazosin
$ 42,00 – $ 332,00Price range: $ 42,00 through $ 332,00
Active substance: Doxazosin
More Details
This product has multiple variants. The options may be chosen on the product page
Eliquis
$ 60,00 – $ 320,00Price range: $ 60,00 through $ 320,00
Active substance: Apixaban
More Details
This product has multiple variants. The options may be chosen on the product page
